

CASE REPORT

Early-stage diffuse large B-cell lymphoma of the submental region: a case report and review of the literature

 R. Patini¹, V. Coviello², M. Riminucci³, A. Corsi³ & A. Cicconetti²
¹Department of Surgical Sciences for Head and Neck Diseases, School of Dentistry, Catholic University of Sacred Heart, Rome, Italy

²Department of Oral and Maxillofacial Sciences, School of Dentistry, 'Sapienza' University of Rome, Rome, Italy

³Department of Experimental Medicine and Pathology, 'Sapienza' University of Rome, 'Umberto I' Polyclinic in Rome, Rome, Italy

Key words:

biopsy, histopathology, mental region, neck, patient management, tumour

Correspondence to:

A Cicconetti
 Department of Oral and Maxillofacial Sciences
 School of Dentistry
 'Sapienza' University of Rome 6
 Caserta St
 00161 Rome
 Italy
 Tel.: +390649976601
 Fax: +390649978143
 email: andrea.cicconetti@uniroma1.it

Accepted: 12 April 2016

doi:10.1111/ors.12221

Abstract

Lymphomas represent the third most common group of malignant lesions in the oral cavity and maxillofacial region, following squamous cell carcinoma and salivary gland neoplasm^{1,2}. Traditionally, lymphomas are divided into two subtypes, Hodgkin lymphomas (HL) and non-Hodgkin lymphomas (NHL)³. The diffuse large B-cell lymphoma (DLBCL) is a rapidly aggressive NHL constituted by big lymphoid cells that can appear as a nodal or extra-nodal disease; about 4% of DLBCL are initially confined to extra-nodal sites⁴. The oral and maxillofacial region is the second most common extra-nodal site, and half of the cases are located in Waldeyer's ring³.

The tumour may present clinical symptoms and radiographic findings as local swelling, pain or discomfort, ulcer and bone resorption mimicking other pathologic lesions such as periodontal disease, pericoronitis, apical radiolucencies or dental abscesses⁵.

We report a case of a patient with DLBCL of the submental region staged at I AE according to the Ann Arbor lymphoma staging system.

Case report

A 65-year-old white woman was admitted to the *Department of Oral and Maxillofacial Sciences of 'Sapienza', University of Rome*, sent by her dentist for the evaluation and treatment of a rapid growing, not painful, fixed lump of the submental region diagnosed as a dental abscess (Fig. 1A,B).

The patient had no significant systemic disease and no smoking habit. Clinical intraoral examination of the soft tissues showed no abnormalities. No lymphadenopathy could be noted. The patient reported no pain when the submental region was palpated. A vitality test of both lower canines and incisors was performed. As all teeth were vital, the diagnosis of dental abscess was rejected.

A computerised tomography (CT) with contrast enhancement showed a multilocular tumour measuring 5 × 6 × 6 located in both laterocervical and submental regions (Fig. 2A,B).

Considering the relevant dimensions of the tumour and the absence of squamous cancer related to medical history findings or clinical signs, such as oral and skin primary lesions, the clinicians decided to avoid unnecessary additional tests and to proceed with an incisional biopsy.

Incisional biopsy was performed under local anaesthesia, and multiple specimens were sent for a histological test. The histological examination showed a diffused proliferation of atypical round cells with lymphoid characteristics positive for CD20, Bcl-6 and MUM1 and negative for CD3, CD5 and D1 cyclin. Ki-67 index was 60% (Fig. 3A–D).

The final diagnosis was NHL consistent with extra-nodal DLBCL staged at I AE according to the Ann Arbor lymphoma staging system.

All blood work was normal. Specifically IgG, β-2 micro globulin and lactic dehydrogenase were all within normal range.




Figure 1 (A, B) Frontal and lateral extraoral view showing the large tumefaction of the submental region after biopsy.




Figure 2 (A, B) Coronal CT scan images with contrast enhancement show a multilocular radiolucent borderline lesion extended both in laterocervical and submental regions.

The patient is under CHOPR treatment monitored at regular intervals by CT scanning.

Discussion

DLBCL is the most common NHL, comprising 30–40% of all cases^{6–9}. Little is known about its cause. Differences in incidence among ethnic groups, as reported by Regezi *et al.*, suggest a genetic influence⁴. In 2011, Corti *et al.* reported 11 cases of NHL of oral cavity in AIDS patients, suggesting that acquired or congenital immunodeficiency is a significant risk factor¹⁰. Iamaroon *et al.* had previously demonstrated that oral NHLs can be caused by an altered immune response to EBV or that specific chromosomal translocation plays a role in the formation of NHLs, causing dysregulation of

oncogenes or oncosuppressor genes and allowing unhindered cell proliferation¹¹.

A lymphoma can arise from regional nodes, and in this case, it is named intranodal lymphoma. Extranodal lymphomas are neoplasms that are often components of a spreading process of a disease, which may involve regional nodes, or they may represent primary extranodal disease^{12–14}. Therefore, the definition of intranodal lymphoma and primarily or secondarily extranodal lymphoma is sometimes difficult. Literature reports say that the decision is based on the opinion of the examining physician who may take into account any intercurrent symptoms like lymphadenopathy¹⁵.

The tumour typically affects middle-aged to older adults in the seventh decade. According to the Ann Arbor lymphoma staging system, stage I indicates




Figure 3 Histological examinations. (A, B) The neoplastic tissue consisted of large lymphoid cells with irregular nuclei and atypical mitosis (H&E stain). (C) Tumour cells expressed the pan B-cell marker CD20. (D) Proliferation fraction as assessed by Ki67 staining.

single lymph node involvement, stage II indicates involvement of lymph nodes on the same side of diaphragm, stage III involves lymph nodes on both sides of diaphragm and stage IV is characterised as diffuse or disseminated involvement. The designation A and B denotes the absence or presence of constitutional symptoms, respectively. The designation E indicates extranodal localisation.

Biopsy, along with tissue-based immunologic studies, is the only reliable way to make a definitive diagnosis. DLBCL consists of sheets of large lymphoid cells with large vesicular nuclei, prominent nucleoli and abundant basophilic cytoplasm^{4,9}.

In head and neck (HN) region, B-cell lymphomas can appear in any location as demonstrated by De Biase *et al.* who presented the case of a primary and exclusive gingival NHL in the symphysis region¹⁶.

Mian *et al.* showed that the HN region is a relatively frequent site of presentation of extranodal DLBCL that can arise in different anatomical subregions. They reported data from 488 patients affected by stage I/II E HN-DLBCL: 300 were located in the Waldeyer's ring, 38 in the parotid and salivary gland, 48 in the thyroid gland, 53 in the nasal cavity and paranasal sinuses, 24 in the palate and oral cavity and 25 in more than one of the previous involved sites¹⁷.

In 2012, Triantafyllidou *et al.* reported 58 extranodal HN-NHL, among them 19 were DLBCL: 6 were I stage, 3 located in paranasal sinus and 3 in Waldeyer's ring; 13 were II stage, 7 located at maxillary mucosa and 6 at mandibular mucosa³.

Lymphomas can also affect peri-implant tissues as recently showed by the report of Jin *et al.* who presented a case of DLBCL of the peri-implant mucosa mimicking peri-implantitis¹⁸.

Even though HN location is common for DLBCL, there is no evidence in literature regarding this neoplasm located in submental region, suggesting that the physician consider this location as extremely rare.

As found in our patient, immunohistochemical expression of B-cell markers CD20 is commonly seen with variable staining with the germinal centre markers Bcl-2, Bcl-6 and MUM1.

Usually, on radiographic imaging, tumours initially take the shape and form of the host bone and some may be mistaken for a dental abscess. The borders are typically blurred due to the invasive nature of the neoplasm. The internal structure is usually completely radiolucent, with occasional patches of radiopacity as well as reactive bone formation. Widening of the mandibular canal has also been described⁵.

DLBCL is considered an aggressive yet treatable tumour with the variable clinical course of a

swelling, painful or painless, with or without ulceration^{19,20}.

An initial remission rate of 60–80% has been reported, and a 5-year survival rate of about 50% is mentioned considering that the involvement of bone is associated with a very poor prognosis³.

Prognostic risk factors include age, tumour stage, number of extranodal sites and serum lactic dehydrogenase levels. The most commonly used chemotherapy protocol is CHOP, acronym for cyclophosphamide, doxorubicin, vincristine and prednisone. These can be associated with a monoclonal antibody, rituximab with positive results in terms of survival. This modified protocol is named R-CHOP.

The use of radiation therapy for the treatment of DLBCL is still controversial since some evidences showed that this combination does not provide a survival advantage.

Generally, the prognosis for indolent lymphomas is poor. Even though survival is long, with a mean time interval of 8 years, they are considered incurable.

With aggressive lymphomas, remission is induced in 40% of patients receiving multiple immunochemotherapy. For those who respond well to chemotherapy, the outlook is good and resolution of the disease may occur after few courses of treatment. However, the outlook is poor for nonresponders, and the disease is usually fatal within several weeks⁵.

In the majority of cases reported in literature, the neoplasm is associated with endodontically treated teeth. This aspect needs to be taken into account because dentists should be on the alert for clinical situations that fail to respond to conventional therapy and avoid multiple procedures without performing a biopsy causing the delay of treatment of what may be an aggressive, neoplastic condition. Primary extranodal NHL can mimic apical abscesses, and misdiagnosis of this condition can delay both diagnosis and initiation of treatment and influence the prognosis and eventual outcome.

Conflict of interest

The authors confirm that they have no conflict of interest.

Ethical Approval

None required.

References

1. Epstein JB, Epstein JD, Le ND, Gorsky M. Characteristics of oral and paraoral malignant lymphoma: a population-based review of 361 cases. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2001;92:519–25.
2. van der Waal RI, Huijgens PC, van der Valk P, van der Waal I. Characteristics of 40 primary extranodal non-Hodgkin lymphomas of the oral cavity in perspective of the new WHO classification and the international prognostic index. *Int J Oral Maxillofac Surg* 2005;34:391–5.
3. Triantafyllidou K, Dimitrakopoulos J, Iordanidis F, Gkagkalis A. Extranodal non-hodgkin lymphomas of the oral cavity and maxillofacial region: a clinical study of 58 cases and review of the literature. *J Oral Maxillofac Surg* 2012;70:2776–85.
4. Regezi JA, Sciubba JJ, Jordan RC. Lymphoid lesions. In: Regezi JA, Sciubba JJ, Jordan RC, editors: *Oral Pathology. Clinical Pathologic Correlations*, 4th edition. St. Louis, MO: Saunders, 2003:220–8.
5. Wong GB, Spadafora S, Barbon N, Caputo M. Primary extranodal B-cell non-hodgkin lymphoma mimicking an endodontic lesion: report of 2 cases. *J Can Dent Assoc* 2013;79:d93.
6. Hart S, Horsman JM, Radstone CR, Hancock H, Goepel JR, Hancock BW. Localised extranodal lymphoma of the head and neck: the Sheffield Lymphoma Group experience (1971–2000). *Clin Oncol (R Coll Radiol)* 2004;16:186–92.
7. Takahashi H, Fujita S, Okabe H, Tsuda N, Tezuka F. Immunophenotypic analysis of extranodal non-Hodgkin's lymphomas in the oral cavity. *Pathol Res Pract* 1993;189:300–11.
8. Shindoh M, Takami T, Arisue M, Yamashita T, Saito T, Kohgo T *et al.* Comparison between submucosal (extra-nodal) and nodal non-Hodgkin's lymphoma (NHL) in the oral and maxillofacial region. *J Oral Pathol Med* 1997;26:283–9.
9. Marx RE, Stern D. Neoplasms of the immune system: lymphomas, leukemias and Langerhans cell histiocytosis. In: Marx RE, Stern D, editors: *Oral and Maxillofacial Pathology. A Rationale for Diagnosis and Treatment*. Chicago, IL: Quintessence Publishing Co., 2003:829–52.
10. Corti M, Villafañe MF, Solari R, De Carolis L, Cangelosi D, Santoro J *et al.* Non-Hodgkin lymphomas of the oral cavity in AIDS patients in a reference hospital of infectious diseases in Argentina: report of eleven cases and review of the literature. *J Gastrointest Cancer*. 2011;42:143–8.
11. Iamaroon A, Pongsiriwet S, Mahanupab P, Kitikamthon R, Pingtong J. Oral non-Hodgkin's lymphomas: studies of EBV and p53 expression. *Oral Dis* 2003;9:14–8.

12. Zucca E, Roggero E, Bertoni F, Conconi A, Cavalli F. Primary extranodal non-Hodgkin's lymphoma. Part 2: head and neck, central nervous system and other less common sites. *Ann Oncol* 1999;10:1023.
13. Boulaadas M, Benazzou S, Sefiani S, Nazih N, Essakalli L, Kzadri M. Primary extranodal non-Hodgkin's lymphoma of the oral cavity. *J Craniofac Surg* 2008;19:1183–5.
14. Kolokotronis A, Kostantinou N, Christakis I *et al.* Localized B-cell non Hodgkin's lymphoma of oral cavity and maxillofacial region: a clinical study. *Oral Surg Oral Med Oral Pathol Oral Radiol Oral Endod* 2005;99:303.
15. Fujita A, Tomita N, Fujita H, Motohashi K, Hyo R, Yamazaki E *et al.* Features of primary extranodal lymphoma in Kanagawa, a human T-cell leukemia virus type 1 nonendemic area in Japan. *Med Oncol* 2009;26:49.
16. De Biase A, Guerra F, Salucci S, Giordano G, Lamazza L. Primary and exclusive gingival localization of non-Hodgkin lymphomas. Case report. *Minerva Stomatol* 2005;54:63–8.
17. Mian M, Capello D, Ventre MB, Grazio D, Svaldi M, Rossi A *et al.* Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study). *Ann Hematol* 2014;93:221–31.
18. Jin SH, Park G, Ko Y, Park JB. Diffuse large B-cell lymphoma of the peri-implant mucosa mimicking peri-implantitis. *J Oral Implantol* 2016;42:220–3.
19. Kemp S, Gallagher G, Kabani S, Noonan V, O'Hara C. Oral non Hodgkin's lymphoma: review of the literature and World Health Organization classification with reference to 40 cases. *Oral Surg Oral Med Oral Pathol Oral Radiol Oral J Endod* 2008;105:194.
20. Urquhart A, Berg R. Hodgkin's and non-Hodgkin's lymphoma of the head and neck. *Laryngoscope* 2001;111:1565–9.